Birchview Capital, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Birchview Capital, LP reported 72 stock positions worth $213.8 million. Its top holding was KLA (KLAC) at 25.2% of the portfolio, followed by Bristol-Myers Squibb (BMY, 8.0%) and Lam Research (LRCX, 7.1%). Compared with Q1 2026, it opened 14 new positions, sold out of 15, added to 17 and reduced 22. The biggest buy was Nektar Therapeutics (NKTR, shares +161%) and the biggest sale Bristol-Myers Squibb (BMY, shares −3%).
- Most Recent 13F
- Q2 2026
- Location
- BURLINGTON, VT
- CIK
- 0001618205
- Portfolio Value
- $213.8M (Q2 2026)
- SEC Filing
- 0001618205-26-000003 ↗ filed Aug 14, 2026
Holdings Value
Holdings 72 stocks · $213.8M
| KLAC KLA Corp. | 25.18% | 178,471 | $53.8M | Reduce -10.2% |
| BMY Bristol-Myers Squibb Co. | 8.01% | 297,243 | $17.1M | Reduce -3.0% |
| LRCX Lam Research Corp. | 7.09% | 35,000 | $15.2M | Reduce -2.8% |
| NTLA Intellia Therapeutics Inc. | 3.17% | 385,900 | $6.8M | Reduce -13.4% |
| SLDB Solid Biosciences Inc. | 3.11% | 666,196 | $6.7M | Add +6.4% |
| BDSX Biodesix Inc. | 3.02% | 286,804 | $6.5M | No change |
| STOK Stoke Therapeutics Inc. | 2.73% | 178,110 | $5.8M | Reduce -15.2% |
| OVV Ovintiv Inc. | 2.65% | 107,500 | $5.7M | No change |
| NKTR Nektar Therapeutics | 2.64% | 81,000 | $5.7M | Add +161.3% |
| CORT Corcept Therapeutics Inc. | 2.33% | 57,200 | $5.0M | Add +21.2% |
| NBIX Neurocrine Biosciences Inc. | 2.14% | 27,190 | $4.6M | No change |
| PRTA Prothena Corp. PLC | 2.06% | 449,019 | $4.4M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 2.02% | 171,000 | $4.3M | No change |
| PTGX Protagonist Therapeutics Inc. | 2.01% | 35,018 | $4.3M | Add +0.1% |
| CMPX Compass Therapeutics Inc. | 1.72% | 1,675,000 | $3.7M | Add +14.3% |
| RLMD Relmada Therapeutics Inc. | 1.32% | 408,100 | $2.8M | Reduce -0.3% |
| ALKS Alkermes PLC | 1.23% | 50,000 | $2.6M | No change |
| HALO Halozyme Therapeutics Inc. | 1.22% | 33,251 | $2.6M | Add +229.2% |
| CLDX Celldex Therapeutics Inc. | 1.22% | 69,900 | $2.6M | Reduce -0.3% |
| CYTK Cytokinetics Inc. | 1.20% | 30,000 | $2.6M | No change |
| OLMA Olema Pharmaceuticals Inc. | 1.16% | 199,000 | $2.5M | Reduce -9.1% |
| VERA Vera Therapeutics Inc. | 1.16% | 57,758 | $2.5M | Add +31.3% |
| UTHR United Therapeutics Corp. | 1.14% | 4,506 | $2.4M | Add +0.1% |
| ZBIO Zenas Biopharma Inc. | 1.11% | 93,601 | $2.4M | Add +33.7% |
| QURE Uniqure NV | 1.09% | 50,697 | $2.3M | Reduce -49.6% |
| PACB Pacific Biosciences of Calif | 1.06% | 1,350,000 | $2.3M | Reduce -10.0% |
| ABVX Abivax SA-ADR | 1.06% | 17,000 | $2.3M | New |
| VIR Vir Biotechnology Inc. | 1.05% | 220,000 | $2.2M | New |
| BIIB Biogen Inc. | 0.91% | 9,000 | $1.9M | Add +80.0% |
| EQT Eqt Corp. | 0.86% | 34,619 | $1.8M | No change |
| BIOA Bioage Labs Inc. | 0.79% | 69,000 | $1.7M | New |
| TVTX Travere Therapeutics Inc. | 0.77% | 29,000 | $1.6M | Reduce -0.7% |
| QDEL Quidelortho Corp. | 0.73% | 89,377 | $1.6M | Add +8.3% |
| AXSM Axsome Therapeutics Inc. | 0.69% | 6,000 | $1.5M | No change |
| FHTX Foghorn Therapeutics Inc. | 0.64% | 281,937 | $1.4M | Add +0.1% |
| BCYC Bicycle Therapeutics PLC-ADR | 0.62% | 313,616 | $1.3M | Reduce -32.4% |
| GPCR Structure Therapeutics Inc. | 0.60% | 24,000 | $1.3M | Reduce -76.0% |
| XENE Xenon Pharmaceuticals Inc. | 0.59% | 21,032 | $1.3M | Add +0.1% |
| NVO Novo-Nordisk A/S-Spons ADR | 0.54% | 24,000 | $1.2M | New |
| FCX Freeport-McMoran Inc. | 0.53% | 18,035 | $1.1M | Reduce -0.0% |
| IMNM Immunome Inc. | 0.50% | 50,000 | $1.1M | No change |
| PHVS Pharvaris NV | 0.48% | 29,847 | $1.0M | No change |
| HROW Harrow Inc. | 0.48% | 24,000 | $1.0M | No change |
| ADAG Adagene Inc.-ADR | 0.47% | 240,000 | $1.0M | New |
| DFTX Definium Therapeutics Inc. | 0.44% | 20,000 | $941K | New |
| SLN Silence Therapeutics PLC-ADR | 0.37% | 71,218 | $782K | New |
| BBIO Bridgebio Pharma Inc. | 0.30% | 8,741 | $651K | Add +0.6% |
| FDMT 4D Molecular Therapeutics Inc. | 0.30% | 48,505 | $645K | New |
| URGN Urogen Pharma Ltd. | 0.28% | 16,487 | $607K | New |
| PHAT Phathom Pharmaceuticals Inc. | 0.28% | 55,000 | $597K | Reduce -71.8% |
| CAMP CAMP4 Therapeutics Corp. | 0.25% | 120,000 | $524K | New |
| SVRA Savara Inc. | 0.23% | 80,000 | $493K | New |
| CADL Candel Therapeutics Inc. | 0.23% | 47,756 | $492K | Reduce -20.4% |
| ALT Altimmune Inc. | 0.22% | 152,681 | $464K | New |
| CMPS Compass Pathways PLC | 0.20% | 30,000 | $425K | Reduce -92.0% |
| KPTI Karyopharm Therapeutics Inc. | 0.20% | 42,952 | $420K | Reduce -48.8% |
| CGEM Cullinan Therapeutics Inc. | 0.17% | 20,000 | $364K | No change |
| TRIN Trinity Capital Inc. | 0.17% | 20,000 | $358K | No change |
| CAPR Capricor Therapeutics Inc. | 0.16% | 14,352 | $346K | New |
| CSTL Castle Biosciences Inc. | 0.14% | 12,984 | $310K | Add +0.7% |
| IVVD Invivyd Inc. | 0.14% | 342,275 | $299K | New |
| GRCE Grace Therapeutics Inc. | 0.13% | 120,000 | $272K | Add +140.0% |
| KBDC Kayne Anderson BDC Inc. | 0.13% | 20,000 | $271K | No change |
| VYGR Voyager Therapeutics Inc. | 0.12% | 75,147 | $263K | Add +0.3% |
| LUNG Pulmonx Corp. | 0.12% | 200,543 | $261K | Reduce -19.9% |
| OCUL Ocular Therapeutix Inc. | 0.09% | 20,655 | $203K | Reduce -93.5% |
| KYNB Kyntra Bio Inc. | 0.08% | 22,566 | $170K | No change |
| ELUT Elutia Inc. | 0.08% | 165,094 | $162K | No change |
| QNRX Quoin Pharmaceuticals LT-ADR | 0.05% | 20,000 | $97K | No change |
| LPCN Lipocine Inc. | 0.02% | 16,712 | $43K | Reduce -85.0% |
| DCGO Docgo Inc. | 0.01% | 39,062 | $20K | Reduce -1.3% |
| GOSS Gossamer Bio Inc. | 0.00% | 18,176 | $3K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| BMY Bristol-Myers Squibb Co. | Reduce -3.0% | 8.01% | −2.56 |
| GPCR Structure Therapeutics Inc. | Reduce -76.0% | 0.60% | −2.14 |
| OCUL Ocular Therapeutix Inc. | Reduce -93.5% | 0.09% | −1.45 |
| NVCR Novocure Ltd. | Sold out | 0.00% | −1.26 |
| STOK Stoke Therapeutics Inc. | Reduce -15.2% | 2.73% | −1.17 |
| CMPS Compass Pathways PLC | Reduce -92.0% | 0.20% | −0.98 |
| ENGN Engene Holdings Inc. | Sold out | 0.00% | −0.97 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -71.8% | 0.28% | −0.95 |
| RARE Ultragenyx Pharmaceutical Inc. | Sold out | 0.00% | −0.74 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -9.1% | 1.16% | −0.69 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −0.65 |
| BCYC Bicycle Therapeutics PLC-ADR | Reduce -32.4% | 0.62% | −0.60 |
| LPCN Lipocine Inc. | Reduce -85.0% | 0.02% | −0.49 |
| VSTM Verastem Inc. | Sold out | 0.00% | −0.45 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.43 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −0.32 |
| IDYA Ideaya Biosciences Inc. | Sold out | 0.00% | −0.32 |
| RCUS Arcus Biosciences Inc. | Sold out | 0.00% | −0.32 |
| RGNX Regenxbio Inc. | Sold out | 0.00% | −0.32 |
| RLMD Relmada Therapeutics Inc. | Reduce -0.3% | 1.32% | −0.30 |
| RCKT Rocket Pharmaceuticals Inc. | Sold out | 0.00% | −0.26 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −0.22 |
| OM Outset Medical Inc. | Sold out | 0.00% | −0.22 |
| NTLA Intellia Therapeutics Inc. | Reduce -13.4% | 3.17% | −0.08 |
| FCX Freeport-McMoran Inc. | Reduce -0.0% | 0.53% | −0.07 |
| KPTI Karyopharm Therapeutics Inc. | Reduce -48.8% | 0.20% | −0.07 |
| PHR Phreesia Inc. | Sold out | 0.00% | −0.07 |
| PACB Pacific Biosciences of Calif | Reduce -10.0% | 1.06% | −0.07 |
| LUNG Pulmonx Corp. | Reduce -19.9% | 0.12% | −0.06 |
| CLDX Celldex Therapeutics Inc. | Reduce -0.3% | 1.22% | −0.05 |
| ZNTL Zentalis Pharmaceuticals Inc. | Sold out | 0.00% | −0.02 |
| DCGO Docgo Inc. | Reduce -1.3% | 0.01% | −0.00 |
| CADL Candel Therapeutics Inc. | Reduce -20.4% | 0.23% | +0.06 |
| QURE Uniqure NV | Reduce -49.6% | 1.09% | +0.15 |
| TVTX Travere Therapeutics Inc. | Reduce -0.7% | 0.77% | +0.28 |
| LRCX Lam Research Corp. | Reduce -2.8% | 7.09% | +2.71 |
| KLAC KLA Corp. | Reduce -10.2% | 25.18% | +8.52 |
Portfolio Buys Q1 2026 → Q2 2026
| NKTR Nektar Therapeutics | Add +161.3% | 2.64% | +1.37 |
| CORT Corcept Therapeutics Inc. | Add +21.2% | 2.33% | +1.24 |
| ABVX Abivax SA-ADR | New | 1.06% | +1.06 |
| VIR Vir Biotechnology Inc. | New | 1.05% | +1.05 |
| HALO Halozyme Therapeutics Inc. | Add +229.2% | 1.22% | +0.85 |
| BIOA Bioage Labs Inc. | New | 0.79% | +0.79 |
| SLDB Solid Biosciences Inc. | Add +6.4% | 3.11% | +0.55 |
| NVO Novo-Nordisk A/S-Spons ADR | New | 0.54% | +0.54 |
| ADAG Adagene Inc.-ADR | New | 0.47% | +0.47 |
| DFTX Definium Therapeutics Inc. | New | 0.44% | +0.44 |
| BIIB Biogen Inc. | Add +80.0% | 0.91% | +0.39 |
| SLN Silence Therapeutics PLC-ADR | New | 0.37% | +0.37 |
| ZBIO Zenas Biopharma Inc. | Add +33.7% | 1.11% | +0.33 |
| FDMT 4D Molecular Therapeutics Inc. | New | 0.30% | +0.30 |
| URGN Urogen Pharma Ltd. | New | 0.28% | +0.28 |
| CAMP CAMP4 Therapeutics Corp. | New | 0.25% | +0.25 |
| SVRA Savara Inc. | New | 0.23% | +0.23 |
| ALT Altimmune Inc. | New | 0.22% | +0.22 |
| CAPR Capricor Therapeutics Inc. | New | 0.16% | +0.16 |
| VERA Vera Therapeutics Inc. | Add +31.3% | 1.16% | +0.15 |
| IVVD Invivyd Inc. | New | 0.14% | +0.14 |
| GRCE Grace Therapeutics Inc. | Add +140.0% | 0.13% | −0.00 |
| CSTL Castle Biosciences Inc. | Add +0.7% | 0.14% | −0.04 |
| QDEL Quidelortho Corp. | Add +8.3% | 0.73% | −0.04 |
| VYGR Voyager Therapeutics Inc. | Add +0.3% | 0.12% | −0.04 |
| BBIO Bridgebio Pharma Inc. | Add +0.6% | 0.30% | −0.06 |
| PTGX Protagonist Therapeutics Inc. | Add +0.1% | 2.01% | −0.09 |
| XENE Xenon Pharmaceuticals Inc. | Add +0.1% | 0.59% | −0.10 |
| FHTX Foghorn Therapeutics Inc. | Add +0.1% | 0.64% | −0.12 |
| UTHR United Therapeutics Corp. | Add +0.1% | 1.14% | −0.38 |
| CMPX Compass Therapeutics Inc. | Add +14.3% | 1.72% | −2.70 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 72 | $213.8M | KLAC, BMY, LRCX, NTLA, SLDB |
| Q1 2026 | 73 | $175.7M | KLAC, BMY, CMPX, LRCX, STOK |
| Q4 2025 | 68 | $170.8M | KLAC, BMY, CMPX, STOK, LRCX |
| Q3 2025 | 69 | $132.4M | KLAC, BMY, CORT, PRTA, STOK |
| Q2 2025 | 71 | $100.7M | BMY, KLAC, CORT, OVV, ACAD |
| Q1 2025 | 68 | $115.2M | BMY, CORT, ACAD, PRTA, BDSX |
| Q4 2024Amended | 68 | $122.9M | BMY, BDSX, ACAD, ELUT, PRTA |
| Q3 2024Amended | 61 | $115.5M | BMY, BDSX, ACAD, ELUT, UTHR |
| Q2 2024Amended | 60 | $108.2M | BMY, BDSX, ELUT, NBIX, SILK |
| Q1 2024Amended | 59 | $122.7M | BMY, NBIX, BDSX, ELUT, ACAD |